SG194998A1 - Amylin peptides and derivatives and uses thereof - Google Patents

Amylin peptides and derivatives and uses thereof Download PDF

Info

Publication number
SG194998A1
SG194998A1 SG2013084892A SG2013084892A SG194998A1 SG 194998 A1 SG194998 A1 SG 194998A1 SG 2013084892 A SG2013084892 A SG 2013084892A SG 2013084892 A SG2013084892 A SG 2013084892A SG 194998 A1 SG194998 A1 SG 194998A1
Authority
SG
Singapore
Prior art keywords
substituted
unsubstituted
xaa
polypeptide
lys
Prior art date
Application number
SG2013084892A
Other languages
English (en)
Inventor
Chengzao Sun
Manoj P Samant
Swetha Neravetla
Original Assignee
Amylin Pharmaceuticals Llc
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Llc, Astrazeneca Pharmaceuticals Lp filed Critical Amylin Pharmaceuticals Llc
Publication of SG194998A1 publication Critical patent/SG194998A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG2013084892A 2011-05-25 2012-05-24 Amylin peptides and derivatives and uses thereof SG194998A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489781P 2011-05-25 2011-05-25
PCT/US2012/039431 WO2012162542A1 (en) 2011-05-25 2012-05-24 Amylin peptides and derivatives and uses thereof

Publications (1)

Publication Number Publication Date
SG194998A1 true SG194998A1 (en) 2013-12-30

Family

ID=47217749

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2013084892A SG194998A1 (en) 2011-05-25 2012-05-24 Amylin peptides and derivatives and uses thereof

Country Status (17)

Country Link
US (1) US20140221287A1 (enExample)
EP (1) EP2714067A1 (enExample)
JP (1) JP2014516049A (enExample)
KR (1) KR20140045433A (enExample)
CN (1) CN103826655A (enExample)
BR (1) BR112013030067A2 (enExample)
CA (1) CA2837104A1 (enExample)
CL (1) CL2013003377A1 (enExample)
CO (1) CO6821894A2 (enExample)
EA (1) EA201391763A1 (enExample)
IL (1) IL229449A0 (enExample)
MX (1) MX2013013802A (enExample)
PH (1) PH12013502385A1 (enExample)
SG (1) SG194998A1 (enExample)
TN (1) TN2013000491A1 (enExample)
WO (1) WO2012162542A1 (enExample)
ZA (1) ZA201309679B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682147C (en) 2007-03-30 2017-08-08 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
MX2017004947A (es) 2014-10-24 2017-06-29 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
WO2018144671A1 (en) * 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
JP2021522231A (ja) * 2018-04-25 2021-08-30 ヤンセン ファーマシューティカ エヌ．ベー． チオエーテル環状ペプチドアミリン受容体調節因子
CA3106384A1 (en) 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
IL317273A (en) 2022-05-27 2025-01-01 Hangzhou Sciwind Biosciences Co Ltd Human Amylin Analog, Derivative and Use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2385878C2 (ru) * 2004-02-11 2010-04-10 Амилин Фармасьютикалз, Инк. Пептид, обладающий свойствами амилина (варианты), и его применение (варианты)
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
EP2036539A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CA2703830A1 (en) * 2007-11-20 2009-05-28 Ambrx, Inc. Modified insulin polypeptides and their uses

Also Published As

Publication number Publication date
KR20140045433A (ko) 2014-04-16
WO2012162542A1 (en) 2012-11-29
MX2013013802A (es) 2014-04-25
NZ618526A (en) 2015-09-25
EA201391763A1 (ru) 2014-04-30
US20140221287A1 (en) 2014-08-07
EP2714067A1 (en) 2014-04-09
TN2013000491A1 (en) 2015-03-30
ZA201309679B (en) 2016-10-26
BR112013030067A2 (pt) 2016-11-29
CN103826655A (zh) 2014-05-28
JP2014516049A (ja) 2014-07-07
CL2013003377A1 (es) 2014-07-04
PH12013502385A1 (en) 2014-01-13
IL229449A0 (en) 2014-01-30
CO6821894A2 (es) 2013-12-31
CA2837104A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
US20140221287A1 (en) Amylin Peptides and Derivatives and Uses Thereof
US20140221282A1 (en) Long duration dual hormone conjugates
US20140249076A1 (en) Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
JP7634531B2 (ja) ｇＩＰおよびＧＬＰ－１デュアルアゴニストポリペプチド化合物、薬学的に許容できる塩、および使用
US9217022B2 (en) GLP-1 receptor agonist compounds having stabilized regions
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
US20150111246A1 (en) Site-specific enzymatic modification of exendins and analogs thereof
US9879063B2 (en) Engineered polypeptides having enhanced duration of action and reduced immunogenicity
US9175061B2 (en) Protein conjugates and methods for their preparation
WO2012130015A1 (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
KR20130036290A (ko) 추가 이황화 결합을 함유하는 인슐린 유도체
JP2017509698A (ja) プレプログルカゴンから誘導可能なペプチドホルモン類似体
WO2015149627A1 (zh) 结构修饰的glp-1类似物及其制备方法
NZ618526B2 (en) Amylin peptides and derivatives and uses thereof
AU2012258714A1 (en) Amylin peptides and derivatives and uses thereof
AU2003273761A1 (en) Glucagon-like peptide-2 variants
HK1198008A (en) Amylin peptides and derivatives and uses thereof
TW202608907A (zh) 肽類似物及使用其之方法
WO2025242218A1 (zh) 一种多肽激动剂，其制备方法及医药用途
TW202615456A (zh) 用於肥胖症及第二型糖尿病（ｔ２ｄｍ）的雙重及三重促效劑化合物